secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0000886163-24-000059
Event type: debt
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Ligand ups revolving credit line to $125M from $75M
---------------------------------------------------

- First amendment to Oct 2023 Credit Agreement executed July 8, 2024, increasing aggregate revolving commitments from $75M to $125M.
- Borrowing capacity expanded by $50M; no other material changes detailed in the filing.
- Credit facility includes subsidiaries as guarantors; Citibank remains administrative agent, swingline lender and L/C issuer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000059/0000886163-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000059/lgnd-20240708.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer